Imatinib Teva Uk (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This inhibition stops downstream signaling that normally promotes cell division and survival, leading to apoptosis of the cancer cells that rely on these kinases.

The specific dose of Imatinib Teva Uk is determined by the prescribing physician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should set the dosing regimen.

Safety data for Imatinib in pregnancy and lactation are limited. The drug may pose risks to the fetus and infant, so it should only be used if the potential benefit justifies the potential harm. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer faster molecular responses in some patients, but Imatinib’s long‑term safety profile and extensive clinical experience make it a widely used choice.

Imatinib Teva Uk should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct light. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Imatinib Teva Uk is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe neutropenia or thrombocytopenia, hepatotoxicity, cardiac dysfunction, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events, and any concerning symptoms reported promptly.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the drug. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking contraindicated strong CYP3A4 inhibitors or inducers without medical supervision.